Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Selenium Nanoparticle-Enriched Lactobacillus Plantarum Causes More Anti-Carcinogenic Effect on Human Colon Cancer Cells Compared to Non-Enriched Ones Publisher



Zare H1 ; Sanaei M1 ; Yazdi MH1, 2 ; Shahverdi AR1, 2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Pharmaceutical Biotechnology and Biotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Recombinant Vaccine Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, 1417614411, Iran

Source: BioNanoScience Published:2023


Abstract

The immunomodulatory effects of Lactobacillus plantarum cell lysate have been demonstrated previously. The purpose of this research is to evaluate the anti-cancer and immunomodulatory effects of non-enriched and selenium nanoparticles-enriched L. plantarum PTCC 1058 cell lysate on the Caco2 cell line. Lactobacillus plantarum cell lysate were added in different concentrations of 100, 50, and 25 µg/mL onto the Caco2 cells and was then followed by a 24-h culture. The MTT assay was used to determine the anti-carcinogenic effect. The results indicated that in both cases, lower concentrations of cell lysate had a greater inhibitory effect on Caco2 cells’ proliferation. However, this effect was significantly stronger in SeNP-enriched cell lysate treated Caco2. We also evaluated the expression of several cytokines in Caco2 cells following 24 h of exposure to 25 µg/mL of non-enriched and SeNP-enriched cell lysate by RT-qPCR. The results demonstrated that both types of cell lysate significantly enhanced IL-12, IFN-γ, and TNF-α expression (P ˂ 0.0001), as well as decreased IL-8, IL-10, and TGF-β expression. It was observed that the magnitudes of these effects were more pronounced for the enriched lysate, suggest that SeNP-enriched L. plantarum cell lysate may be effective in bolstering the immune responses of cancer patients. © 2023, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.